Bajaj Healthcare has informed that the company has received an approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule. The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product’s availability in the domestic market. The press release in this regard, being issued by the Company is submitted. Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 & the Company’s code of Internal Procedures and Conduct for Regulating, monitoring & reporting of trading in securities, the Trading window for dealing in securities of the company shall continue to remain closed for all the Directors and Designated Employees in terms of its earlier disclosure dated 27th December 2024.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1714.25 |
Dr. Reddys Lab | 1149.75 |
Cipla | 1452.70 |
Lupin | 2009.40 |
Zydus Lifesciences | 891.25 |
View more.. |